A5042333042- Erythropoietin and Anemia Treatment
- Glaucoma and retinal disorders
- Potassium and Related Disorders
- Hemoglobinopathies and Related Disorders
- Ophthalmology and Eye Disorders
- Chronic Disease Management Strategies
- Iron Metabolism and Disorders
- Health Systems, Economic Evaluations, Quality of Life
- Corneal surgery and disorders
- Dialysis and Renal Disease Management
- Acute Myocardial Infarction Research
- Ocular Surface and Contact Lens
- Cardiac Health and Mental Health
- Chronic Kidney Disease and Diabetes
- Diabetes Treatment and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Imaging and Diagnostics
- Heart Failure Treatment and Management
- Membrane-based Ion Separation Techniques
- Cardiovascular Function and Risk Factors
- Social and Educational Sciences
- Blood Pressure and Hypertension Studies
- Advanced Causal Inference Techniques
- Bipolar Disorder and Treatment
- Statistical Methods in Clinical Trials
AstraZeneca (Sweden)
2018-2024
AstraZeneca (Brazil)
2021-2024
Wilmington University
2020
AstraZeneca (United States)
2020
AstraZeneca (United Kingdom)
2019
George Institute for Global Health
2018
University of Oxford
2018
Uppsala University Hospital
2000-2005
1928 Diagnostics (Sweden)
2003
Campo Arqueologico de Mertola
2003
Abstract Background Routine clinical evidence is limited on outcomes associated with anemia in patients severe chronic kidney disease (CKD). Methods We linked population-based medical databases to identify individuals CKD (eGFR < 30 mL/min/1.73 m 2 ) Northern Denmark from 2000 2016, including prevalent as of 1 January 2009 or incident hereafter into the study. classified non-anemic (≥ 12/≥ 13 g/dl hemoglobin (Hgb) women/men), grade (10–12/13 Hgb (8–10 Hgb), and 3+ (< 8 allowing persons...
Objective To assess associations of health-related quality life (HRQoL) with patient profile, resource use, cardiovascular (CV) events and mortality in stable patients post-myocardial infarction (MI). Methods The global, prospective, observational TIGRIS Study enrolled 9126 1–3 years post-MI. HRQoL was assessed at enrolment 6-month intervals using the patient-reported EuroQol-5 dimension (EQ-5D) questionnaire, scores anchored 0 (worst possible) 1 (perfect health). Resource CV were recorded...
Abstract Previously lacking in the literature, we describe longitudinal patterns of anemia prescriptions for non-dialysis-dependent chronic kidney disease (NDD-CKD) patients under nephrologist care. We analyzed data from 2818 Stage 3-5 NDD-CKD Brazil, Germany, and US, naïve to medications (oral iron, intravenous [IV] or erythropoiesis stimulating agent [ESA]) at enrollment CKDopps. report cumulative incidence function (CIF) medication initiation stratified by baseline characteristics. Even...
Optimal management of anemia chronic kidney disease (CKD) remains controversial. This retrospective study aimed to describe the epidemiology and selected clinical outcomes in patients with CKD US.Data were extracted from Henry Ford Health System databases. Adults stages 3a-5 not on dialysis (estimated glomerular filtration rate < 60 mL/min/1.73m2) between January 1, 2013 December 31, 2017 identified. Patients renal replacement therapy or active cancer bleeding excluded. followed for ≥12...
This study determined the rate of response to latanoprost compared with timolol in patients glaucoma or ocular hypertension, whether some convert from non-responders responders after more prolonged therapy, and this conversion represents a delayed random fluctuation.In previously described, multicenter, randomized, double-masked, parallel group study, received either 0.005% once daily (n = 128) 0.5% twice 140) for 6 months. Intraocular pressure (IOP) was assessed at baseline 0.5, 1.5, 3,...
Real-world data for patients with chronic kidney disease (CKD), specifically pertaining to clinical management, metabolic control, treatment patterns, quality of life (QoL) and dietary are limited. Understanding these gaps using real-world, routine care will improve our understanding the challenges consequences faced by CKD, facilitate long-term goal improving their management prognosis.DISCOVER CKD follows an enriched hybrid study design, both retrospective prospective patient cohorts,...
Abstract Background Risk prediction tools are lacking for patients with stable disease some years after myocardial infarction (MI). Hypothesis A practical long‐term cardiovascular risk index can be developed. Methods The long‐Term rIsk, Clinical manaGement and healthcare Resource utilization of coronary artery dISease in post‐myocardial prospective global registry enrolled 1 to 3 post‐MI (369 centers; 25 countries), all ≥1 factor (age ≥65 years, diabetes mellitus requiring medication, second...
Background Chronic kidney disease (CKD) is a major global health burden, and associated with increased adverse outcomes, poor quality of life, substantial care costs. While there an increasing need to build patient-centered pathways for improving CKD management in clinical care, data this field are scarce. Objective The aim study was understand patient-reported experiences, symptoms, treatment journeys among patients through retrospective qualitative approach based on available...
Abstract Background Hyperkalemia is common among hemodialysis (HD) patients and has been associated with adverse clinical outcomes. Previous studies considered a single serum potassium (K) measurement or time-averaged values, but K excursions out of the target range may be more reflective true hyperkalemia events. We assessed whether lead to an elevated risk Methods Using data from 21 countries in Phases 4–6 (2009–18) Dialysis Outcomes Practice Patterns Study (DOPPS), we investigated...
Objectives Traditional potassium (K + ) binders for treating hyperkalaemia are unpalatable and poorly tolerated. Newer K reportedly better tolerated; however, no published data describe their palatability, a determinant of long-term adherence. This study evaluated the palatability preference three binders: sodium calcium polystyrene sulfonate (S/CPS), zirconium cyclosilicate (SZC) patiromer sorbitex (patiromer). Design Phase 4, randomised, participant-blinded, cross-over study. Participants...
Anemia is prevalent in patients with chronic kidney disease (CKD), but the longitudinal risk of anemia newly identified CKD unknown. We therefore examined risks experiencing persons CKD.This cohort study included adult stages 3-5 defined by an estimated glomerular filtration rate (eGFR) level <60 mL/min/1.73m2 (at least two measurements ≥90 days apart) ascertained from a population-based registry complete laboratory test results Northern Denmark (population ~2.2 million) during 2009-2016....
<b><i>Introduction:</i></b> Further understanding of adverse clinical events in patients with chronic kidney disease (CKD) is needed. This study aimed to describe characteristics nondialysis-dependent (NDD) and dialysis-dependent (DD) CKD assess incidence rates uncommon interest these patients. <b><i>Methods:</i></b> retrospective used electronic medical record data from USA (≥18 years) estimated glomerular filtration rate (eGFR) &#x3c;60...
Further understanding of adverse clinical event rates in patients with chronic kidney disease (CKD) is required for improved quality care. This study described baseline characteristics, rates, and mortality risk CKD, accounting CKD stage dialysis status.
Insights on the differences in clinical outcomes, quality of life (QoL) and health resource utilisation (HRU) with different levels care available to post-acute myocardial infarction (AMI) populations rural urban settings are limited. The long-Term rIsk, manaGement, healthcare Resource stable coronary artery dISease (TIGRIS), a prospective, observational registry, enrolled 8452 patients aged ≥50 years 1-3 post-AMI from June 2013 November 2014 24 countries Asia Pacific/Australia, Europe,...
Objective Atrial fibrillation (AF) and myocardial infarction (MI) are commonly comorbid associated with adverse outcomes. Little is known about the impact of AF on quality life outcomes post-MI. We compared characteristics, clinical in stable patients post-MI with/without AF. Methods/results The prospective, international, observational TIGRIS (long Term rIsk, manaGement healthcare Resource utilization coronary artery dISease) registry included 8406 aged ≥50 years ≥1 atherothrombotic risk...
To evaluate the potential of a Cox marginal structural model (MSM) to estimate time-varying causal inference known clinical trial association where effectiveness inhaled corticosteroid- (ICS-) versus non-ICS-containing treatments has been compared in patients with chronic obstructive pulmonary disease (COPD).This retrospective study from 2006-2016 used linked data Clinical Practice Research Datalink-GOLD, Hospital Episode Statistics, and Office for National Statistics mortality. A MSM,...
Abstract Background Diabetes mellitus (DM) is associated with increased cardiovascular (CV) risk. We compared health‐related quality of life (HRQoL), healthcare resource utilization (HRU), and clinical outcomes stable post‐myocardial infarction (MI) patients without DM. Hypothesis In post‐MI patients, DM worse HRQoL, HRU, outcomes. Methods The prospective, observational long‐term risk, management, Resource coronary artery disease study obtained data from 8968 aged ≥50 years 1 to 3 (369...